Table 1.

Effect of voxelotor on Hb levels and markers of hemolysis and erythrocyte deformability (n = 15)

BaselineFollow-up at 3 monthsP value
Hemoglobin, g/dL 7.4 (6.9-8.1) 9.7 (7.9-11) .002 
Reticulocyte count, 109 per L 289 (230-331) 185 (126-257) .006 
Total bilirubin, μmol/L 59 (38-113) 37 (19-61) .001 
LDH, U/L 504 (365-678) 318 (272-590) .003 
HbF, % 6.8 (3.1-8.3) 3.3 (1.0-6.3) <.001 
Point of sickling, mm Hg 20.1 (17.5-26.1) 16.1 (10.3-18.1) .006 
EImax 0.33 (0.24-0.42) 0.38 (0.28-0.48) .029 
EImin 0.13 (0.07-0.26) 0.21 (0.16-0.41) .007 
BaselineFollow-up at 3 monthsP value
Hemoglobin, g/dL 7.4 (6.9-8.1) 9.7 (7.9-11) .002 
Reticulocyte count, 109 per L 289 (230-331) 185 (126-257) .006 
Total bilirubin, μmol/L 59 (38-113) 37 (19-61) .001 
LDH, U/L 504 (365-678) 318 (272-590) .003 
HbF, % 6.8 (3.1-8.3) 3.3 (1.0-6.3) <.001 
Point of sickling, mm Hg 20.1 (17.5-26.1) 16.1 (10.3-18.1) .006 
EImax 0.33 (0.24-0.42) 0.38 (0.28-0.48) .029 
EImin 0.13 (0.07-0.26) 0.21 (0.16-0.41) .007 

Data are median (interquartile range).

LDH, lactate dehydrogenase.

or Create an Account

Close Modal
Close Modal